Amphotericin B-related nephrotoxicity in low-risk patients

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 2, 2006, Pages 94-99

  Berdichevski, Roberto Herz ^a,c,d   Luis, Luciano Billodre ^b   Crestana, Letícia ^b   Manfro, Roberto Ceratti ^a,b,c  

^a Post Graduate Medical Sciences   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d NONE   (Brazil)

Author keywords

Acute renal failure; Amphotericin B; Nephrotoxicity; Sodium chloride

Indexed keywords

ACICLOVIR; AMPHOB; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CAPTOPRIL; CREATININE; IMMUNOSUPPRESSIVE AGENT; SODIUM CHLORIDE; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD ANALYSIS; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG COST; DRUG SAFETY; FEMALE; FLUID THERAPY; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION TEST; MALE; MYCOSIS; NEPHROTOXICITY; REFERENCE VALUE; RISK ASSESSMENT; URINALYSIS;

EID: 33746864920     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000200005     Document Type: Article

References (20)

1. Mandell G.L., Petri W.A. Jr. Antimicrobial Agents. In: Hardman J.G., Limbird L.E. eds. Goodman and Gilman's - The Pharmacological Basis of Therapeutics. New York, US: McGraw-Hill, 1996;1165-8.
2. Patel R. Antifungal agents - Part I- Amphotericin B preparations and flucytosine. Mayo Clin Proc 1998;73:1205-25.
3. Sawaya B.P., Briggs J.P., Schuermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol 1995;6:154-64.
4. Tolins J.P., Raij L. Chronic amphotericin B nephrotoxicity in the rat, protective effect of prophylactic salt loading. Am J Kidney Dis 1988;11:313-7.
5. Sabra R., Takahashi K., Branch R.A., Badr K.F. Mechanisms of amphotericin B-induced reduction of the glomerular filtration rate: a micropuncture study. J Pharmacol Exp Therap 1990;253:34-7; 65:500-6.
6. Bhathena D.B., Bullock W.E., Nuttall C.E., Luke R.G. The effects of amphotericin B therapy on the intrarenal vasculature and renal tubules in man. Clin Nephrol 1978;9:103-10.
7. Hedemann H.T., Gerkens J.F., Spickard W.A. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-81.
8. Arning M., Scharf R.E. Prevention of amphotericin B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenchr 1989;67:1020-8.
9. Llanos A., Cieza J., Bernardo J., Echevarria J., et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991;40:302-8.
10. Mayer J., Doubek M., Doubek J., et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002 Aug 1;186:379-88.
11. Branch R.A., Jackson E.K., Jacqz E., et al. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr 1987;65:500-6.
12. Ericksson U., Burkhard S., Schaffner A. Comparison of effects of amphotericin B deoxicolate infused over 4 or 24 hours: randomized controlled trial. BMJ 2001;322:1-6.
13. Nucci M., Loureiro M., Silveira F., et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother 1999;43:1445-8.
14. Johnson P.C., Wheat L.J., Cloud G.A., et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002;137:105-9.
15. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haemathol 1997;98:711-8.
16. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. New Engl J Med 1999;340:764-71.
17. Wingard J.R., White M.H., Anaissie E.,et al. A randomized, double-blind comparative trial evaluating the safety of lipossomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infec Dis 2000;31:1155-63.
18. Bates D.W., Su L., Yu D.T., et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452-9.
19. Seguro A.C., Shimizu M.H., Monteiro J.L., et al. Effect of potassium depletion in ischemic renal failure. Nephron 1989;51:350-4.
20. Bernardo J.F., Murakami S., Branch R.A., Sabra R. Potassium depletion potentiates amphotericin B- induced toxicity to renal tubules. Nephron 1995;70:235-41.